Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD

Blood

Volumn 105, Issue 10, 2005, Pages 4035-4042

  Claessens, Yann Erick ^b   Park, Sophie ^b   Dubart Kupperschmitt, Anne ^b   Mariot, Virginie ^b   Garrido, Carmen ^b   Chrétien, Stany ^b   Dreyfus, François ^b   Lacombe, Catherine ^b   Mayeux, Patrick ^b   Fontenay, Michaëla ^a  

^a Service d'Hematologie Biologique ^*  (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CASPASE 8; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MUTANT PROTEIN; PROTEIN DR4; PROTEIN DR5; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW CELL; BURST FORMING UNIT E; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIGAND BINDING; MALE; MYELODYSPLASTIC SYNDROME; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SYNDROME DELINEATION;

EID: 20844462217     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3166     Document Type: Article

References (55)

1. Steensma DP, Tefferi A. The myelodysptastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27:95-120.
2. Aul C, Germing U, Gattermann N, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res. 1998;22:93-100.
3. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993;7:81-107.
4. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68-75.
5. Casadevall N, Durieux P, Dubois S, et al. Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating factor (rHuG-CSF) for the treatment of myelodysplastic syndromes (MDS) on anemia, costs and quality of life: a randomized controlled trial. Blood. 2004;104:321-327.
6. Harris NL, Jaffe ES, Diebold J, et al.. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
7. Greenberg P, Anderson J, de Witte T, et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol. 2000;18:3447-3452.
8. Howe RB, Porwit-MacDonald A, Wanat R. Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood. 2004;103:3265-3270.
9. Greenberg P, International Prognostic Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997;9:2079-2088.
10. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 1993;7;144-146.
11. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268-276.
12. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839-845.
13. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647-656.
14. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10:26-35.
15. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995;81:505-512.
16. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 1996;85:803-815.
17. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299-308.
18. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 1997;7:831-836.
19. Medema JP, Scaffidi C, Kischkel FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997;16:2794-2804.
20. Tehranchi R, Fadeel B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood. 2003;101:1080-1086.
21. Matthes TW, Meyer G, Samii K, Beris P. Increased apoptosis in acquired sideroblastic anaemia. Br J Haematol. 2000;111:843-852.
22. Gupta P, Niehans GA, LeRoy SC, et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB sub-type and anemia, and predicts survival. Leukemia. 1999;13:44-53.
23. Claessens YE, Bouscary D, Dupont JM, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplaslic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99:1594-1601.
24. Bruey JM, Ducasse C, Bonniaud P, et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol. 2000;2:645-652.
25. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72:9873-9880.
26. Sirven A, Ravet E, Charneau P, et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther. 2001;3:438-448.
27. Amsellem S, Ravet E, Fichelson S, Pflumio F, Dubart-Kupperschmitt A. Maximal lentivirus-mediated gene transfer and sustained transgene expression in human hematopoietic primitive cells and their progeny. Mol Ther. 2002;6:673-677.
28. Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann T. A general method for the generation of high-liter, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA. 1994;91:9564-9568.
29. Grell M, Zimmermann G, Gottfried E, et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999;18:3034-3043.
30. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with eioposide and TRAIL. Mol Cell Biol. 2000;20:205-212.
31. Rytomaa M, Martins LM, Downward J. Involvement of FADD and caspase-8 signaling in detachment-induced apoptosis. Curr Biol. 1999;9:1043-1046.
32. Backx B, Broeders L, Touw I, Lowenberg B. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia. 1993;7:75-79.
33. Fontenay-Roupie M, Bouscary D, Guesnu M, et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol. 1999;106:464-473.
34. Juvonen E, Aimolahti A, Volin L, Ruutu T. The prognostic value of in vitro cultures of erythroid and megakaryocyte progenitors in myelodysplastic syndromes. Leuk Res. 1999;23:889-894.
35. Fuhler GM, Hooijenga F, Drayer AL, Vellenga E. Reduced expression of flavocytochrome b558, a component of the NADPH oxidase complex, in neutrophils from patients with myelodysplasia. Hxp Hematol. 2003, 31:752-759.
36. Deeg HJ, Beckham C, Loken MR, et al. Negative regulators ot hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma. 2000;37:405-414.
37. Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood. 2002;100:4427-4432.
38. + cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia. 2003;17:2460-2466.
39. Micheau O, Thome M, Schneider P, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem. 2002;277:45162-45170.
40. Secchiero P, Melloni E, Heikinheimo M, et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood. 2004;103:517-522.
41. Schmidt U, Van Den Akker E, Parren-Van Amelsvoort M, et al. Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J Exp Med. 2004;199:785-795.
42. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res. 2002;26:677-686
43. Maciejewski JP, Risitano AM, Sloand EM, et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol. 2002;117:119-126.
44. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 2001;98:3058-3065.
45. Hueber AO. Role of membrane microdomain rafts in TNFR-mediated signal transduction. Cell Death Differ. 2003;10:7-9.
46. Lozupone F, Lugini L, Matarrese P, et al. Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin. J Biol Chem. 2004;279:9199-9207.
47. Chao W, Shen Y, Li L, Rosenzweig A, Importance of FADD signaling in serum deprivation- and hypoxia-induced cardiomyocyte apoptosis. J Biol Chem. 2002;277:31639-31645.
48. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 1998;392:296-300.
49. Zermati Y, Garrido C, Amsellem S, et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med. 2001;193:247-254.
50. Watanabe-Fukunaga R, Brannan CL, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314-317.
51. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969-976.
52. Walsh CM, Wen BG, Chinnaiyan AM, O'Rourke K, Dixit VM, Hedrick SM. A role for FADD in T cell activation and development. Immunity. 1998;8:439-449.
53. Grambihler A, Higuchi H, Bronk SF, Gores GJ. cFLIP-L inhibits p38 MAPK activation: an additional anti-apoptotic mechanism in bile acid-mediated apoptosis. J Biol Chem. 2003;278:26831-26837.
54. Miyake Y, Kakeya H, Kataoka T, Osada H. Epoxy-cyclohexenone inhibits Fas-mediated apoptosis by blocking activation of pro-caspase-8 in the death-inducing signaling complex. J Biol Chem. 2003;278:11213-11220.
55. Buerger C, Groner B. Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling. J Cancer Res Clin Oncol. 2003;129:669-675.